UCSF is the lead institution for the first-ever NIH-funded pediatric stroke treatment trial – FOCAS: Focal Cerebral Arteriopathy Steroid. The trial will determine the best treatment approach for this inflammatory arteriopathy that causes stroke in previously healthy children. Children must be enrolled within 96 hours of their stroke onset.